VRAX - Virax Biolabs Group Ltd Company Long-Term Debts

Graphic logo of Virax Biolabs Corp (VRAX)

Virax Biolabs Group (VRAX) dominates the preventive diagnostics segment through AI-driven immunity analysis and low demand elasticity. Patents and government contracts ensure a high barrier to entry. This price action chart on GURU.Markets shows that the metric stands at 0.00. The business is currently expanding its portfolio, pivoting from a narrow profile of viral tests toward the detection of cancer and autoimmune disorders.

Virax Biolabs Group (VRAX) - Company Long-Term Debts from 04/28/2023 to 10/31/2026

Virax Biolabs Group Ltd - analytical breakdowns and key metrics (VRAX)

- share price and expert price forecast:
Share Price viraxbiolabs.com|VRAX - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Virax Biolabs|VRAX - Total Company Value
- book value of equity indicators:
Equity per Share Virax Biolabs|VRAX - Book Capitalization|Market Capitalization to Book Value Ratio viraxbiolabs.com|VRAX - Aggregate Company Assets
- debt level and financial liquidity data:
Debt to Equity Virax Biolabs Group|VRAX - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Virax Biolabs Corp|VRAX - Company Debts|Debts to Net Assets Virax Biolabs|VRAX - Company Long-Term Debts|Short-Term Debt Volume Virax Biolabs|Interim Coverage Ratio viraxbiolabs.com
- earnings and valuation multiples indicators:
VRAX - Net Income
Analysis of all company metrics:VRAX viraxbiolabs.com
Manufactured products of Virax Biolabs

Virax Biolabs Group (VRAX) dominates preventive medicine through AI-driven immunity analysis and inelastic demand. This indicator captures total liabilities with a maturity of over one year, reflecting a balance sheet optimization strategy. The stability of this metric confirms bankruptcy resilience during the business recovery period. Investors should consider potential profit stagnation in the absence of clear momentum. By analyzing the company's long-term debt volume, one can assess the issuer's actual financial protection.

Who Virax Biolabs Group competes with

A: Company Long-Term Indebtedness|Quest Diagnostics Incorporated - Company Long-Term Debts|ILMN - Company Long-Term Debts|Cologuard (EXAS) - Company Long-Term Debt|Company Long-Term Indebtedness RVTY|BIO (Bio-Rad Laboratories) - Company Long-Term Debts|Company Long-Term Debts anbio.com|Company Long-Term Debt Sotera Health (SHC)|Company Long-Term Debt QDEL (Quidel Corporation)|OPKO Corp - Company Long-Term Liabilities|CareDx (CDNA) - Long-Term Debt|MRVI - Company Long-Term Debt|Long-Term Debt Volume fulgentgenetics.com FLGT|LAB: Company Long-Term Debts|CTKB - Long-Term Debt Volume|Company Long-Term Debt OraSure Technologies Inc|Exagen Diagnostics (XGN) - Long-Term Debt Volume|Company Long-Term Liabilities MDXH (MDxHealth SA)|Company Long-Term Debt LUCD (luciddx.com)|Company Long-Term Debts PRE (Prenetics)|Long-Term Debt Volume Insight Molecular Diagnostics, Inc. (IMDX)|TRIB - Company Long-Term Debt|Company Long-Term Loans and Borrowings PRPH (ProPhase Labs Corp)|AIMD: Company Long-Term Debts|codiagnostics.com (CODX) - Company Long-Term Debts|Company Long-Term Liabilities HSCS|Company Long-Term Indebtedness BMRA (Biomerica Inc.)|Company Long-Term Liabilities CDIO (Cardio Diagnostics)|BJDX (Bluejay Diagnostics Corp) - Company Long-Term Loans and Borrowings|Company Long-Term Debts AWH (Aspira Women's Health)|acceleratediagnostics.com - Company Long-Term Debt|CENTOGENE - Company Long-Term Debts|Long-Term Debt Volume Enzo Biochem, Inc. ENZ|fresh2.co (FRES) - Company Long-Term Debt|Long-Term Debt Genetic Technologies Limited (GENE)|Company Long-Term Debt 23andMe Holding Co.|Company Long-Term Debt PMD